Targeting T Cell Co-receptors for Cancer Therapy

被引:408
作者
Callahan, Margaret K. [1 ,2 ]
Postow, Michael A. [1 ,2 ]
Wolchok, Jedd D. [1 ,2 ,3 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Melanoma & Immunotherapeut Serv, New York, NY 10065 USA
[2] Cornell Univ, Weill Cornell Med Coll, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Ludwig Ctr Canc Immunotherapy, New York, NY 10065 USA
关键词
LYMPHOCYTE-ASSOCIATED ANTIGEN-4; IPILIMUMAB PLUS DACARBAZINE; RESISTANT PROSTATE-CANCER; METASTATIC MELANOMA; UNTREATED MELANOMA; LUNG-CANCER; PD-1; BLOCKADE; PHASE-3; TRIAL; AUTOIMMUNE HYPOPHYSITIS; ANTI-PD-L1; ANTIBODY;
D O I
10.1016/j.immuni.2016.04.023
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Checkpoint-blocking antibodies can generate potent anti-tumor responses by encouraging the immune system to seek and destroy cancer cells. At this time, the United States Food and Drug Administration has approved three checkpoint-blocking antibodies in three disease indications, and additional approvals are expected to broaden the clinical scope of immunotherapy. Herein, we review the clinical development of CTLA-4-, PD-1-, and PD-L1-blocking antibodies across tumor types and briefly discuss areas of active investigation of potential biomarkers.
引用
收藏
页码:1069 / 1078
页数:10
相关论文
共 71 条
[1]   Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].
Anderson, Ana C. ;
Joller, Nicole ;
Kuchroo, Vijay K. .
IMMUNITY, 2016, 44 (05) :989-1004
[2]  
Andrews Stephanie, 2012, Cancer Manag Res, V4, P299, DOI 10.2147/CMAR.S31873
[3]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[4]   Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies [J].
Ascierto, Paolo A. ;
Simeone, Ester ;
Sznol, Mario ;
Fu, Yang-Xin ;
Melero, Ignacio .
SEMINARS IN ONCOLOGY, 2010, 37 (05) :508-516
[5]   CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation [J].
Bashey, Asad ;
Medina, Bridget ;
Corringham, Sue ;
Pasek, Mildred ;
Carrier, Ewa ;
Vrooman, Linda ;
Lowy, Israel ;
Solomon, Scott R. ;
Morris, Lawrence E. ;
Holland, H. Kent ;
Mason, James R. ;
Alyea, Edwin P. ;
Soiffer, Robert J. ;
Ball, Edward D. .
BLOOD, 2009, 113 (07) :1581-1588
[6]   Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 [J].
Beck, Kimberly E. ;
Blansfield, Joseph A. ;
Tran, Khoi Q. ;
Feldman, Andrew L. ;
Hughes, Marybeth S. ;
Royal, Richard E. ;
Kammula, Udai S. ;
Topalian, Suzanne L. ;
Sherry, Richard M. ;
Kleiner, David ;
Quezado, Martha ;
Lowy, Israel ;
Yellin, Michael ;
Rosenberg, Steven A. ;
Yang, James C. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2283-2289
[7]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[8]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[9]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[10]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175